Breast Cancer | Topics

 
Adjuvant Olaparib Approved in European Union for BRCA1/2-Positive, HER2-Negative High-Risk Early Breast Cancer
August 05, 2022

The European Commission approved olaparib as monotherapy or in combination with endocrine therapy for patients with germline BRCA1/2-mutant, HER2-negative high-risk early breast cancer.

Identifying Use of ctDNA Across Tumor Types
August 04, 2022

Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.

Understanding the Mechanisms and Use of ctDNA and MRD Testing
August 04, 2022

Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.

Prone Vs Supine Adjuvant Radiotherapy Reduces Skin Toxicities in Patients With Breast Cancer and Large Breast Size
August 02, 2022

Treatment with adjuvant radiotherapy in the prone position lowered the odds of desquamation in patients with breast cancer and large breast size.

Mark Pegram, MD, Discusses Major Takeaways From the IDEAL Trial in HR+ Breast Cancer
July 29, 2022

Mark Pegram, MD, spoke the most important data from the IDEAL trial he believes his colleagues should take away.

Valentina Boni, MD, PhD, Talks Safety of Lurbinectedin Monotherapy in Pretreated BRCA-Associated Advanced Breast Cancer
July 26, 2022

Valentina Boni, MD, PhD, spoke about the safety profile observed of lurbinectedin monotherapy and future analyses for patients with BRCA1/2-associated metastatic breast cancer.

Hope S. Rugo, MD, Talks Aromatase Inhibitors Plus Ribociclib in HR+/HER2– Advanced Breast Cancer
July 25, 2022

Hope S. Rugo, MD, FASCO, gave an overview of ribociclib plus aromatase inhibitor use vs abemaciclib plus aromatase inhibitors for patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Fulvestrant Plus Capivasertib Improved Survival Vs Fulvestrant/Placebo in ER+, HER2– Advanced Breast Cancer
July 25, 2022

Findings from the phase 1/2 FAKTION trial indicated that survival had increased following the addition of capivasertib to fulvestrant for patients with aromatase inhibitor–resistant, estrogen receptor–positive, HER2-negative advanced breast cancer.

Hope S. Rugo, MD, on Comparing CDK4/6 Inhibitors in HR+/HER2– Advanced Breast Cancer
July 24, 2022

Hope S. Rugo, MD, FASCO, reviewed data from a matching-adjusted indirect comparison study which analyzed quality of life in patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with ribociclib- or abemaciclib-based regimens.

Medicaid Associated With Reduction in Racial/Ethnic Disparities in De Novo Stage IV Breast Cancer
July 19, 2022

Investigators reported a reduction in racial and ethnic disparities among patients with de novo stage IV breast cancer following implementation of Medicaid expansion, and included a decreased risk of death for patients in a racial/ethnic minority compared with White patients.